Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of avelumab + axitinib in advanced thymic epithelial tumors
2017-004048-38Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and axitinib in thymoma, thymic carcinoma (TC) and thymic malignancies (TET), sponsored by European Institute of Oncology. Primary endpoint: Overall response rate by RECIST 1.1. Started Jun 2021; status: terminated.
02
Drugs
avelumabaxitinib
03
Conditions
thymomathymic carcinoma (TC)thymic malignancies (TET)
Beyond the preview
Go deeper on 2017-004048-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004048-38.